RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study

Recursion Pharmaceuticals (RXRX) announced that it has dosed the first patient in its early-stage study of investigational candidate, REC-3565, for treating relapsed or refractory (R/R) B-cell lymphomas. REC-3565 is a selective MALT1 inhibitor developed using the company’s proprietary AI-driven Recursion OS platform.   The candidate’s unique mechanism of action is expected to notably lower the risk of drug-drug interactions and hyperbilirubinemia observed in other MALT1 inhibitors, potentially allowing for ...